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Abstract
Alzheimer’s disease (AD) is a continuum consisting of a preclinical stage that occurs
decades before symptoms appear. As researchers make advances in investigating the
continuum, the importance of developing drugs for secondary prevention is garner-
ing increased discussion. For efficacious drug development for secondary prevention
it is important to define what are the earliest biological stages of AD. The Alzheimer’s
Association Research Roundtable convenedNovember 27 to 28, 2018 to focus on pre-
clinical AD. This reviewwill address the biological approach to defining pre-clinical AD,
detection, identification of at-risk individuals, and lessons learned from trials such as
A4 and TOMMORROW.
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1 INTRODUCTION
More than 50 million people worldwide are living with dementia,
with Alzheimer’s disease (AD) being the most frequent etiology. This
number is expected to exceed 130 million by 2050 if nothing is done
to slow or prevent the spectrum of dementia from developing.1This
article focuses on strategies to address AD, acknowledging that “pure”
AD (amyloid and tau pathology in isolation) is uncommon and that
AD more routinely exists in the presence of other misfolded proteins
(eg, alpha synuclein, TAR DNA-binding protein 43 or TDP-43) and/or
vascular disease.2 Despite tens of billions of dollars invested by var-
ious organizations over the past 20 plus years, no therapies have yet
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emerged that have slowed the clinical course of AD. At the same time,
significant progress has been achieved in our understanding of AD
pathophysiology and on the development of soluble and imaging (and,
more recently, digital) biomarkers that enable diagnosis even before
there is any clinical symptomatology. The implications for the field are
enormous.Most important is that anunderstandingof the courseof the
disease at such an early time pointwill allow for the testing of potential
therapeutic modalities before there is significant pathology and at a
timewhen therapeutic interventionmay have its greatest impact.
Delaying the onset of AD has the potential not only to improve
the quality of life, lessen disability, and support independent living
for millions of people worldwide, but also to reduce the tremendous
global economic impact of the disease. Preventing AD, however, can
be accomplished only if the disease can be identified and treated
before neurodegenerationhas resulted in pathologies sufficient for the
appearance of clinical symptomatology. Preclinical AD is the term used
to describe the disease state in people who have pathological evidence
of the AD process but no clinical signs and symptoms. A recent multi-
state model used to forecast the prevalence of preclinical and clinical
AD estimated that in 2017, a total of 46.7 million Americans had pre-
clinical AD compared with ≈3.65 million with clinical (mild-severe AD
spectrum) AD and 2.43 million with mild cognitive impairment (MCI).3
By 2060, the number of people with preclinical AD is expected to rise
to about 75 million in the United States. According to this model, pre-
clinical AD affects 38% of the U.S. population over the age of 50. Glob-
ally, these numbers are much higher. Many people with preclinical AD,
however, may not go on to develop ADdementia because of competing
morbidities and other factors that are not well understood.4 However,
with improving strategies for detection and greater longevity, the num-
ber of people who progress may actually increase.
Accurate identification of preclinical AD may allow successful ther-
apies to delay or prevent the onset of clinical and functional symp-
tomatology that results in a diagnosis of dementia. Yet given the poten-
tial high cost of AD drugs in development, the cost of providing those
drugs to all patients with preclinical AD would likely lead to a massive
increase in total prescription costs, as well as for costs for detection
and infusion therapy. These costs theoretically would be offset over
time by a reduction in the amount spent caring for people with AD
dementia, which in 2010 was estimated to total about $200 billion in
the United States alone.5
Moreover, the shift in paradigm from treating people with clinical
disease to those with preclinical disease presents challenges for drug
developers, regulators, clinicians, and health systems, as well as ethi-
cal challenges and concerns about the potential for overdiagnosis and
obligatory treatment that may extend out for decades, resulting in
explosive prescription costs. Because only some proportion of individ-
uals who have the pathologic (biomarker) signature of ADwill progress
to demonstrate memory impairment, and only a subset of those will
continue to progress to the point where the memory/cognitive impair-
ments progress to the point of impairing function (“dementia” diag-
nosis), there must be a clear benefit-risk profile for the treatment of
biomarker-positive, clinically asymptomatic individuals at the greatest
risk for developing dementia over very extended periods. For all these
reasons, the Alzheimer’s Association Research Roundtable focused its
Fall 2018 meeting on preclinical AD, providing a forum for experts
fromacademia, industry, and regulatory agencies todiscuss the current
understanding of preclinical AD and the opportunities and challenges
that must be overcome to translate that understanding into effective
strategies for preventing dementia.
2 DEFINING PRECLINICAL AD
According to the National Institute on Aging/Alzheimer’s Association
Research Framework, which defines AD biologically rather than clin-
ically, preclinical AD may be defined through the use of biomark-
ers. In this conceptualization, biomarkers are grouped according to
the neuropathologic process measured: A for amyloid, T for tau, and
(N) for neurodegeneration/neuronal injury. The (N) biomarker group
is placed in parentheses to indicate that although useful for staging,
these measures are not specific for AD and thus are not diagnostic
biomarkers. The AT(N) classification system is rooted in the hypothet-
ical biomarker curves proposed by Jack et al. in 20106 and updated
in 20137 (Figure 1), which have been generally supported by addi-
tional clinical pathological data from prospective studies in autosomal
dominant autosomal dominant AD (ADAD),8 sporadic AD, and aging
cohorts.7 These data support the hypothesis that cerebral amyloid
beta (Aβ) pathology can be detected in the cerebrospinal fluid (CSF)
as reduced concentration of aggregation-prone Aβ42 protein, and as
aggregates in the brain by positron emission tomography (PET), 15 to
25 years before clinical symptoms appear.9,10 Furthermore, these data
indicate that tau is detectable in the CSF about 10 to 15 years before
the onset of symptoms,9,11 and closer to symptom onset by tau PET.12
It is this period in the disease continuum that is considered preclini-
cal, when there is only biomarker-based evidence of pathology with no
obvious cognitive clinical symptoms.13,14
The Research Framework is flexible with regard to the addition
of other putative and validated disease biomarkers, as they become
available; for example, markers of decline in glucose metabolism mea-
sured with fluorodeoxyglucose PET (FDG-PET),8-10 hippocampal atro-
phy or cortical thinning assessed with magnetic resonance imag-
ing (MRI),15 microglial activation assessed by CSF-soluble triggering
receptor expressed on myeloid cells-2 (TREM2) level,16 or neuronal
injurymarkers such as neurofilament light.17-19 These biomarkersmay,
with further validation, also be used to identify preclinical populations
for secondary prevention studies.
The operationalization of the National Institute on Aging and
Alzheimer’s Association (NIA-AA) staging scheme was also evaluated
from a clinical perspective. This led the committee to create a numer-
ical staging scheme for individuals in the AD continuum. According to
this staging system, Stages 1 and 2 represent preclinical AD. In a 2018
guidance on early AD, the U.S. Food and Drug Administration (FDA)
also recognized six stages, with Stage 2 akin to early MCI, thus provid-
ing a regulatory pathway to drug approval using this staging scheme.20
The Mayo Clinic Study of Aging was used as a platform to discuss
the implementation of a variety of clinical measures to characterize
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F IGURE 1 Dynamic biomarker model: modified amyloid cascade. Time-shifted curves representing the biomarkers temporal manner of
pathophysiologic processes incorporating the ATN classification framework with (A) for amyloid, T for tau, (N) for neurodegeneration or neuronal
injury, and additional (C) for cognitive clinical symptoms. The horizontal axis represents time and the vertical axis represents biomarker severity
(abnormality) from normal (min) to abnormal (max) with the black horizontal line denoting the detection threshold.
the stages. Operationalizing Stage 2 was particularly challenging, with
measures proposed to characterize the objective and subjective cog-
nitive dimensions as well as neurobehavioral symptoms. Among these
three defining characteristics, a change in cognition was the most fre-
quently used measure to characterize people in Stage 2. When the
stages were assessed for stability longitudinally, Stage 2 appeared to
be the most labile. That is, over 40 percent of the persons originally
classified as Stage 2 reverted to Stage 1 when re-evaluated 15months
after the initial assessment. However, in the presence of greater amy-
loid levels, fewer individuals reverted to Stage 1. Caution is needed to
interpret these results, however, due to the many variables that come
into play with regard to operationalizing the various stages. Additional
research on longitudinal clinical progression is needed. Nevertheless,
the staging scheme appears to be useful for delineating individuals
along the cognitive continuum of persons who were amyloid positive,
and this proposed scheme may be useful to further define individuals
whowouldbeeligible for randomized controlled trials in preclinicalAD.
3 GATHERING EVIDENCE TO SUPPORT
TREATING AD AT THE PRECLINICAL STAGE
Secondary prevention trials for AD are those that target individuals
who are clinically normal but have pathological signs indicating that
the disease process is underway; that is, those with preclinical AD.21
The Anti-Amyloid Treatment in Asymptomatic AD (A4) Trial is an
example of a secondary prevention trial because it is enrolling people
with evidence of elevated brain amyloid.22 Other relevant trials
currently underway include primary prevention studies in high-risk
participants who have not yet manifested pathological signs of AD;
The Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU)
is enrolling young, cognitively healthy individuals with autosomal dom-
inant highly penetrant mutations that cause autosomal dominant AD
(ADAD)with almost 100% certainty andwho are up to 15 years before
their estimated age at disease onset. The Alzheimer’s Prevention
Initiative (API) is also conducting a study in individuals with ADAD.
The API-ADAD trial will enroll asymptomatic PSEN1 E280A mutation
carriers from family kindred with ADAD in Colombia.23 DIAN-TU is
also planning a Primary Prevention study that will enroll participants
18 years and olderwho arewithout evidence of Aβ-PET pathology. The
development of the DIAN-TU platform trial will allow for enrollment
of multiple intervention arms simultaneously and consecutively and
the sharing of placebo data between different interventions in order
tomaximize trial efficiency and power.24
3.1 The challenge of detecting preclinical AD
Imaging and fluid biomarkersmay be useful in detecting preclinical AD.
Blood-based biomarkers offer substantial advantages for screening
large populations due to their reduced invasiveness, lower costs,
and increased acceptance by patients, but improving sensitivity and
reliability is key to recognizing these advantages.25 Several large inter-
national consortia have been established to advance the development
of blood-based biomarkers.26-29 Cognitive changes, sleep quality, and
behavior may also offer opportunities to detect preclinical AD, as
discussed below.
3.1.1 Biomarkers of preclinical AD
Imaging biomarkers that may be helpful in identifying preclinical AD
in individuals who are cognitively unimpaired include amyloid and
tau aggregation load as determined using PET, and neurodegenera-
tion and neuronal injury as measured by structural magnetic reso-
nance imaging (MRI) and glucose hypometabolism as measured by
FDG-PET. Three amyloid PET ligands—florbetapir, florbetaben, and
flutemetamol)—are currently approved, andanew ligand, fluselenamyl,
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is in development.30-33 The three approved agents are specific for Aβ
plaques or Aβ in the vessel walls, and images produced from PET scans
with all three ligands correlate with autopsy findings. However, known
limits to the sensitivity of each agent mean that a negative scan does
not prove the absence of Aβ deposits in all cases.
Several tau radioligands are currently being evaluated in clinical
research studies. The most well studied at this point is flortaucipir
(18F-AV-1451), which binds specifically to 3R and 4R tau (the isoforms
thatmake up the paired helical filaments in theADbrain), generally fol-
lows the topographic distribution of neurofibrillary tangles described
in typical AD by Braak et al., and produces images that show binding in
areas of the brain where neurodegeneration is associated with cogni-
tive impairment.34 It is currently under review by the FDA. As is the
case with amyloid PET, tau PET has sensitivity limitations as well as
off-target binding, whichmay compromise diagnostic accuracy.35 Mea-
sures of neurodegeneration, atrophy, and hypometabolism reflect loss
(MRI) or dysfunction (FDG-PET) of dendritic spines, synapses, and neu-
rons, but neither measure is specific for AD; however, their prognostic
value increases when combinedwith biomarkers of amyloid and tau.
CSF biomarkers may also be used as markers of A, T, and (N).
CSF Aβ42 is well accepted as a marker of the pathophysiologic state
associated with development of senile plaque pathology.36 Low levels
correlate well with amyloid PET37-38 with a concordance of ≈90%,
which increases as the disease progresses.39 CSF Aβ42 declines to its
minimum level at least 5 to 10 years before dementia develops, indicat-
ing its usefulness as a preclinical marker40-41; however, it is less useful
at the symptomatic stage and may have greater limits as an outcome
measure in preclinical AD trials. CSF Aβ42 may also be reduced in
the presence of neuroinflammation, normal pressure hydrocephalus,
and other disease states; and there may also be constitutively low Aβ
producers who are close to the Aβ42 cut point for positivity. Fortu-
nately, using the ratio of CSF Aβ42/Aβ40 corrects for this problem and
provides an accurate biomarker for early AD,42 which is easy to inter-
pret, has a robust correlation to pathology, becomes clearly abnormal,
and does not change over time in symptomatic disease. Moreover,
in recent years, fully automated assays with low variation have
become available, along with standardized reference methods and
materials.
CSF tau is more complicated. CSF total tau (T-tau) and phosphory-
lated tau (P-tau) are strongly associated with AD.43 A recent study of
the relationship between CSF T-tau and P-tau and tau PET using the
ligand flortaucipir (18F-AV-1451) showed thatCSFP-tau andT-tau are
elevated in preclinical AD and may appear even before the deposition
of tau.44 The lack of correlationwith tau-PET and post-mortempathol-
ogy suggests that CSF tau may reflect a disturbance in disease home-
ostasis rather than the pathologic burden of tau deposits.
Neurofilament light (NFL) protein is a component of the neural
cytoskeleton. Its presence in the CSF reflects damage or degeneration
of neurons.45 Elevated levels ofCSFNFLare seen inmanyneurodegen-
erative diseases including AD,46 where CSF NFL concentrations begin
to increase in the early stages of disease and continue to increase over
time.47 High levels are associated with disease progression, more pro-
nounced cognitive decline, and faster brain atrophy.
NFL has also shown promise as a plasma biomarker of neurodegen-
eration for AD. Several studies have shown that plasmaNFL correlates
with CSF NFL and neuroimaging markers as an indicator of neurode-
generation across theAD continuum, is higher in peoplewith bothMCI
and AD, even after correcting for age,48 and is associated with cog-
nitive decline and neuroimaging biomarkers of AD.18,19,49 Serum NFL
concentration increases 5 to 15 years prior to clinical disease onset in
familial AD andmay thus be an easily accessible biomarker for onset of
neurodegeneration.19
Other plasma biomarkers have also shown some promise. Blood
amyloid biomarkers results have been somewhat inconsistent in the
literature50,51; however, plasmaAβ42/40 ratiomeasuredbymass spec-
trometry has been shown to provide a sensitive and reliable measure
of amyloid status that predicts future progression to positive amyloid
PET and correlates with CSF Aβ42/40.51-52 Plasma T-tau is elevated in
persons with AD as well as other brain disorders,53-55 and plasma P-
tau has been shown to be a sensitive and specific predictor of elevated
brain Aβ, which suggests it may be useful for screening,56 although
more research is needed on the topic.
Plasma is also being tested with explorative mass spectrometry
approaches to identify changes in the proteome that reflect differ-
ent disease states.57 The Accelerating Medicines Partnership for AD
(AMP-AD) has undertaken a multi-institute, large-scale proteomics
approach to profile proteomic changes across the AD continuum.
Designed to provide a deeper understanding of the molecular mech-
anisms underlying disease progression, these studies may also identify
biomarkers that can be used in clinical trials and clinically.
Roundtable participants stressed the need to be realistic about the
utility of blood biomarkers. They may be ideal for large-scale screen-
ing in primary care clinics where they can reach broad populations to
rule out Aβ positivity. However, for other contexts of use, such as a
biomarker of progression, more research is needed. The infrastructure
is in place to validate several screeningmarkers; however, itwill be nec-
essary to identify and quantify sources of variability.
3.1.2 Psychometric approaches to detecting
preclinical AD
By definition, cognition remains in norm.al limits in older adults classi-
fied with preclinical AD. Despite the absence of abnormality, multiple
longitudinal studies have shown that in cognitively normal individuals,
positive Aβ biomarkers are associated with increased risk of progres-
sion to MCI and dementia.58-61 Furthermore, even before clinical dis-
ease progression, serial neuropsychological assessments showpositive
Aβ biomarkers to be associated with subtle (i.e., Cohen’s d = ∼0.5) but
relentless decline in cognition when compared to change in matched
Aβ-negative controls.
In preclinical AD, amyloid-related cognitive decline is most evident
in episodicmemory, although there is also evidence for decline in other
domains, including attention, language, and visuospatial function and
when such measures of cognition are combined into constructs such
as global cognitive function.62 Strong associations between cognitive
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decline and the presence of abnormal biomarkersmakes cognitive out-
come measures optimal end points for clinical trials of drugs designed
to forestall the development of AD. The Preclinical Alzheimer’s Cog-
nitive Composite (PACC) is a global outcome measure developed
in accordance with recommendations from the FDA that cognitive
changes used to assess drug effects in preclinical AD reflect perfor-
mance across multiple aspects of cognition as well as considering the
importance of memory decline in the disease. PACC scores and similar
cognitive composites are being used currently as cognitive end points
in theA4 andGeneration studies. PACC scores can be derived from the
neuropsychological batteries used in many of the large natural history
studies, and in each case such scores have been shown to adequately
capture progression of disease throughout the preclinical stages.63
3.1.3 Subjective cognitive decline and mild
behavioral impairment in preclinical AD
Subjective cognitive decline (SCD) is associated with an increased risk
of progression to MCI and dementia and may be one of the first cog-
nitive symptoms of AD, associated with biomarker positivity.64 SCD is
detectable in preclinical AD using self- and informant-reported sub-
jective memory questionnaires and neuropsychological assessments,
including tools such as the PACC, ECog, Blessedmemory test, andCog-
nitive Change Index (CCI).65-67 SCD-plus criteria include complaints of
memory impairment over other domains, onset of cognitive complaints
within the last 5 years or over the age of 60, concerns over cognitive
decline worse than others of a similar age, confirmation of cognitive
decline by an informant, and apolipoprotein E gene (APOE) ε4 carriage;
and increase the likelihood that SCD reflects preclinical AD.68 How-
ever, SCD may also be associated with psychiatric symptoms includ-
ing depression and anxiety, the presence of which may confound the
assessment of SCD.66
Changes in behavior and personality, better framed as neuropsychi-
atric symptoms (NPS), are included in thediagnostic criteria for demen-
tia, including dementia of theAlzheimer’s type, frontotemporal demen-
tia (FTD), and vascular dementia.69 Evidence suggests, however, that
NPS emerge frequently in advance of cognitive impairment. A recent
analysis of National Alzheimer’s Coordinating Center data demon-
strated that of those participants who developed AD, 30% developed
NPS in advance of MCI.70 Patients who develop dementia are often
given psychiatric diagnoses for what are early manifestations of neu-
rodegenerativedisease71-73; thusbetter awarenessofNPSaspotential
markers of incident cognitive decline and dementia is required.
Mild behavioral impairment (MBI) is a validated syndrome that char-
acterizes these later-life acquired and sustained NPS and frames them
as an at-risk state for incident cognitive decline and dementia. For
somepreclinical individuals,MBI is the indexmanifestationof neurode-
generation, observed in advance of cognitive impairment.73-75 MBI is
associated with faster cognitive decline in a large community popula-
tion with normal cognition76 and has shown to significantly increase
the progression rate to dementia in those with normal cognition or
MCI.77 MBI has demonstrated a higher conversion rate to dementia
than a psychiatric comparator group consisting of late-life psychiatric
disorders,78 highlighting the distinction between MBI and psychiatric
disorders.72 Thus, detecting early theNPS that constituteMBImay aid
in earlier detection of dementia at the preclinical or prodromal phase,
in advance of or in addition to cognitive impairment.
Further exploration of MBI prognostication for incident cognitive
decline and dementia is part of the research agenda in this field,79
but early results suggest that MBI may be an easily implemented
approach to capture an enriched biomarker-positive group of older
adults with normal cognition, providing a chance for earlier interven-
tion and enrollment in prevention trials.79 Thus, screening for emer-
gent neuropsychiatric symptoms may provide a simple and efficient
method to identify a high-risk population for dementia.
3.1.4 Sleep quality and preclinical AD
Poor sleep is associatedwith decreased cognitive performance in older
adults,80,81 and excessive daytime sleepiness (EDS) was shown to be
predictive of cognitive decline in the French Three City Study.82 More-
over, in the Baltimore Longitudinal Study of Aging, EDSwas associated
with amyloid positivity.83 Short sleep duration (<6 hours per night) is
associated with greater amyloid burden84; and prolonged sleep dura-
tion (>9 hours per night) has been shown to be associated with an
increased risk of dementia,85 further indicating that disrupted sleep
may be an early marker of neurodegeneration.
In preclinical AD, individuals with the lowest sleep efficiency com-
pared to thosewith thebest sleepefficiencywere5 timesmore likely to
have elevated Aβ.86 Aβ pathology has also been associated with longer
sleep latency.87 Among those at risk for AD, worse subjective sleep
quality, increased sleep problems, and EDS were shown to be asso-
ciated with increased Aβ and tau86,87; and baseline EDS was associ-
ated with increased Aβ accumulation in the nondemented elderly, sug-
gesting that the presence of EDS indicates increased vulnerability to
pathological changes associated with AD.88 Because the association
between sleep and AD appears to be bidirectional, treating late-life
sleep disturbancemay help prevent or slow the development of AD.
3.1.5 Polygenic risk prediction of preclinical AD
Genetic data obtained in genome-wide association studies (GWAS) by
the International Genomics of Alzheimer’s Project (IGAP) has been
used to calculatepolygenic risk scores (PRS) that predictADwith ahigh
degree of accuracy.89 PRS can be used to identify candidates for trials
and may, with further validation, be useful to inform treatment deci-
sions and help patients and families plan for the future. A caveat in the
use of PRS is that they are applicable only to the population fromwhich
theywere derived, which currentlymeans people of European descent.
They also should be used in combination with other disease indices.
Similar to PRS, polygenic hazard scores (PHSs) predict absolute
age-related risk, which may be more useful in identifying people in
the preclinical stage of disease. Desikan et al. developed a PHS that
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retrospectively predicted age of onset and rate of progression to
AD in asymptomatic older adults and showed that it correlates with
biomarker and neuropathology measures.90 They went on to show
that the PHS could be used prospectively to predict rate of progression
to AD in individuals with both preclinical AD and MCI, and that the
PHS was more strongly predictive compared to APOE status alone.91
In addition, they showed that the combination of PHS and biomarkers
status predicted accelerated clinical progression.92 PHS may thus be
useful both to enrich preclinical AD trials with biomarker-positive
individuals and as a stratificationmarker in clinical trials.
3.1.6 Digital biomarkers
Digital biomarkers have also attracted attention as potentially useful
in the detection of subtle cognitive and functional changes in the early
stages of AD and may also be useful as sensitive secondary end points
in clinical trials. Wearable devices, smartphones, and infrared sensors
are all capable of capturing continuous high-dimensional data that
reflect health-related aspects of daily life (eg, walking, remembering
to take medication, using a computer, sleeping, and social interac-
tions), which are inherently ecologically valid and meaningful. These
measures have not yet been widely deployed in clinical research,
and increased efforts are needed to more fully understand how best
to deploy and integrate them into trials as well as interpret and
analyze data with confidence.93-97 There is great promise that digital
biomarkers could identify those at high risk of developing clinical AD
for primary prevention and trial enrichment or be used for sensitive
secondary end points in clinical trials. TheNational Institutes of Health
andVeterans Administration (NIH-VA) supportedCART (Collaborative
Aging Research using Technology) platform is addressing this need,
providing an open, technology-agnostic, end-to-end system for the
research community.98 In Europe, academic and industrial leaders
in the field of AD recently announced the launch of “RADAR-AD”
(Remote Assessment of Disease And Relapse—AD). The collaborative
research program aims to develop technologies that remotely identify
andmeasure “digital biomarkers” to assess the progression of earlyAD.
3.1.7 Participant registries
Patient registries are critical for engaging participants in the clinical
trial process and recruiting and enrolling them in trials. For preclinical
prevention AD trials, large cohorts need to be recruited, assessed, and
monitored longitudinally through a variety of approaches.
One such registry is the Brain Health Registry (BHR), which was
established in 2014 at the University of California, San Francisco as
an online project to recruit individuals interested in brain health and,
potentially, in clinical studies of AD and other brain disorders. BHR has
enrolled over 60,000 participants, with the majority in their 50s and
60s,with thousandsover theageof70.More thanhalf of thoseenrolled
have a family history of AD. Among those age 55 and older, nearly half
have memory concerns. BHR uses a computerized test battery99 val-
idated for online administration. This test used longitudinally allows
BHRto identify individualswithdeclining cognitionwhomaybeeligible
and appropriate for prevention trials, and then refer willing individuals
to trial sites.
3.2 Ethical and regulatory aspects of developing
treatments for preclinical AD
Both the European Medicines Agency (EMA) and FDA have published
guidelines for testing compounds in early AD,100,101 and both of these
guidelines rely heavily on biomarkers, applied in various contexts of
use, which can include selecting patients, capturing disease progres-
sion, measuring drug exposure, or demonstrating drug effects.100,101
Moreover, both agencies emphasize the need for precompetitive shar-
ing of rigorously collected standardized data across the AD scientific
community in order to understand disease progression and its relevant
sources of variability. In Japan, drugs that target preclinical AD might
be evaluated through their “Conditional Early Approval System” that
aims to put highly useful and effective drugs into practice as quickly as
possible. Early approval may rely on biomarkers as primary end points,
only if a correlation has been demonstrated between the biomarker
and a clinical effect.
3.2.1 Bioethical considerations in the translation
of preclinical AD from research into practice
New criteria for defining preclinical AD are introducing ethical chal-
lenges because cognitively normal people may suddenly come face-to-
face with terms such as “preclinical Alzheimer’s pathological change.”
An adjunct to theA4 Study, SOKRATES (Study of Knowledge andReac-
tions to Amyloid Testing) is exploring the experience of learning one’s
amyloid status.102 Core aspects of this experience are concerns about
how the level of amyloid corresponds to the risk of decline, how to
interpret subtle cognitive changes, and how elevated amyloid might
affect one’s relationship with others, plans for the future, and feelings
of self-control and self-determination.
3.3 Moving forward: lessons learned from
secondary prevention trials in preclinical AD
In 2011, investigators from three academic-led prevention initiatives—
DIAN, A4, and API—came together to form the Collaboration for
Alzheimer’s Prevention (CAP). The aim of the umbrella group was to
harmonize efforts, avoid duplication, share data, and jointly seek regu-
latory guidance. Subsequently the group was expanded to include the
industry-funded TOMMORROW trial and the European Prevention
of Alzheimer’s Disease (EPAD). In 2016, CAP published principles to
guide data and sample sharing in preclinical AD trials.103 Sponsors and
companies involved in these trials have agreed to these principles, as
have many other sponsors who are conducting large clinical trials in
the AD space.
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Continued efforts are also needed to address constraints to data
sharing, including concerns about (1) maintaining scientific integrity of
trials, (2) not compromising the ability of a study towithstand indepen-
dent scientific scrutiny, and (3) maintaining the confidentiality of trial
participants, particularly those with autosomal dominant mutations or
genetic risk factors. Functional platforms are also needed to ensure
data interoperability.
Themain challenge, however, is finding drugs that effectively halt or
forestall the development of AD symptoms. Despite many disappoint-
ing trial results, there remains optimism that an effective treatment is
within reach and that prevention trials in AD will play a critical role in
identifying sucheffective treatments.Moreover, there is broad support
for continuedefforts at lifestyle factors that decrease theburdenofAD
in the population at large, a blood test to efficiently and inexpensively
detect preclinical AD and qualify biomarkers and other end points in
order to use accelerated approval mechanisms and to address other
scientific, regulatory, financial, ethical, social, organizational, and logis-
tical challenges.
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